Nataly V. Uboha
Affiliations: | Yale University, New Haven, CT |
Area:
Molecular PsychiatryGoogle:
"Nataly Uboha"Mean distance: 14.13 (cluster 6) | S | N | B | C | P |
Cross-listing: PsychTree
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Uboha NV, Lubner SJ, LoConte NK, et al. (2020) Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors. Investigational New Drugs |
Dhakras P, Uboha N, Horner V, et al. (2020) Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma Translational Gastroenterology and Hepatology. 5: 55-55 |
Uboha NV, Eickhoff JC, Chandrasekharan C, et al. (2020) Phase II study of the combination of abemaciclib and pembrolizumab in locally advanced unresectable or metastatic gastroesophageal adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149. Journal of Clinical Oncology. 38: TPS461-TPS461 |
Uboha NV, Lubner SJ, LoConte NK, et al. (2020) Phase I dose-escalation trial of trifluridine/tipiracil (TAS-102) and temozolomide in the treatment of advanced neuroendocrine tumors. Journal of Clinical Oncology. 38: 615-615 |
Kratz JD, Gillette A, Rehman S, et al. (2020) Defining population response of patient-derived colorectal cancer organoids against prospective clinical outcomes. Journal of Clinical Oncology. 38: 177-177 |
Goyal L, Lamarca A, Strickler JH, et al. (2020) The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA). Journal of Clinical Oncology. 38: e16686-e16686 |
Kratz JD, LoConte NK, Lubner SJ, et al. (2020) Efficacy of single-agent epidermal growth factor receptor inhibition in the second-line setting for metastatic colorectal cancer with a goal towards retreatment strategies. Journal of Clinical Oncology. 38: e16035-e16035 |
Boni V, Burris III HA, Liu JF, et al. (2020) CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC). Journal of Clinical Oncology. 38: 526-526 |
Deming DA, Emmerich P, Turk AA, et al. (2020) Pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver oligometastatic MSS/MMR proficient colorectal cancer (CRC). Journal of Clinical Oncology. 38: 4046-4046 |
Emmerich P, Matkowskyj KA, McGregor S, et al. (2020) VCAN accumulation and proteolysis as predictors of T lymphocyte-excluded and permissive tumor microenvironments. Journal of Clinical Oncology. 38: 3127-3127 |